COG Cambridge Cognition Holdings Plc

TIDMCOG

Cambridge Cognition Holdings PLC

17 August 2022

Cambridge Cognition Holdings Plc

(" Cambridge Cognition" or the "Company")

Cambridge Cognition selected by the University of Oxford

as a cognitive assessment partner for the ISAP study

Alzheimer's Disease Validation for NeuroVocalix (TM)

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid Positivity ("ISAP") study. As a consequence Cambridge Cognition expects to receive validation data for its voice-based solution, NeuroVocalixTM. The randomised controlled trial, s ponsored by the University of Oxford and funded by Novo Nordisk, aims to investigate the effectiveness of a diabetes medication (oral semaglutide) against the neuropathophysiology of Alzheimer's disease (specifically, tau accumulation and neuroinflammation).

Alzheimer's disease is characterised by the abnormal build-up of amyloid and tau proteins in the brain(1) , which can occur years before clinical symptoms such as memory loss are detected. More than 57.4 million people worldwide are living with dementia and, without new therapeutics to slow or halt disease progression, this number is expected to grow to 152.8 million by 2050(2) . To assess the potential for a new therapeutic approach, the University of Oxford has launched the ISAP study.

The ISAP study will focus on developing a treatment for the earliest signs of Alzheimer's disease by recruiting participants who are at increased risk of developing dementia. Semaglutide is a diabetes medication that animal studies suggest could reduce phospho-tau accumulation and improve cognitive function(3) . The ISAP study will track whether semaglutide can reduce participants' tau pathology and neuroinflammation over the course of a year by repeating MRI and PET imaging at the start of the study and 52 weeks. To accurately assess cognitive change, participants will be asked to perform Cambridge Cognition's digital assessments, CANTAB(TM) and NeuroVocalix(TM) , at the start of the study, week 26 and week 52.

This trial will combine both touchscreen and voice-based cognitive assessments to track the earliest signs of dementia and the extent to which semaglutide can slow or halt disease progression. The University of Oxford has selected Cambridge Cognition as a cognitive assessment partner for this trial because the company offers several sensitive measures of cognitive processes that are compromised in early Alzheimer's disease.

To find out more about the ISAP study, please visit the University of Oxford website: https://www.dtu.ox.ac.uk/ISAP/

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We are delighted to be partnering with the University of Oxford to develop better treatments for Alzheimer's disease. We are particularly pleased to be including our voice solution, NeuroVocalix(TM), as we believe it could help track the earliest cognitive indicators of dementia and this study is an important step as we gather further validation data. We have seen strong early uptake of NeuroVocalix(TM) following launch to the academic community last year and more than 20 institutions are using it."

Ivan Koychev, Chief Investigator of ISAP, said:

"The ISAP study paves the way for novel and much needed therapies for Alzheimer's disease. Glucagon-like peptide-1 receptor agonist medications such as semaglutide are particularly promising given the emerging evidence of reduced dementia incidence in patients who take them as part of their diabetes treatment. We are grateful to our commercial partners Novo Nordisk and Cambridge Cognition for their support of this study."

References

   1.    https://www.nhs.uk/conditions/alzheimers-disease/causes/ 
   2.    https://www.alzheimers.org.uk/about-us/news-and-media/facts-media 

3. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=39097

For further information, contact:

 
 Cambridge Cognition Holdings Plc               Tel: 012 2381 0700 
  Matthew Stork, Chief Executive Officer         press@camcog.com 
  Stephen Symonds, Chief Financial Officer 
 Panmure Gordon (UK) Limited (NOMAD and Joint   Tel: 020 7886 2968 
  Broker)                                        (Corporate Finance) 
  Freddy Crossley / Emma Earl                    (Corporate Broking) 
  Rupert Dearden 
 Dowgate Capital Limited (Joint Broker)         Tel: 020 3903 7715 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)         Tel: 020 3934 6630 
  Tim Metcalfe / Graham Herring / Zach Cohen 
 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABIGDIGGBDGDL

(END) Dow Jones Newswires

August 17, 2022 02:00 ET (06:00 GMT)

Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024